FDA Awards Priority Review Voucher to Sponsor of Rare Pediatric Disease Product

Summary

The FDA has awarded a priority review voucher to Marathon Pharmaceuticals, LLC, for its rare pediatric disease product EMFLAZA, following a review of the product's eligibility under the FD&C Act and FDASIA.